PMID- 34530896 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210919 IS - 1750-9378 (Print) IS - 1750-9378 (Electronic) IS - 1750-9378 (Linking) VI - 16 IP - 1 DP - 2021 Sep 16 TI - HPV16 E6-specific T cell response and HLA-A alleles are related to the prognosis of patients with cervical cancer. PG - 61 LID - 10.1186/s13027-021-00395-y [doi] LID - 61 AB - BACKGROUND: T cell epitopes are polypeptide fragments presented to T cell receptors by MHC molecules encoded by human leukocyte antigen (HLA) genes after antigen-presenting cell processing, which is the basis for the study of antigen immune mechanism and multi-epitope vaccine. This study investigated T cell response to HPV16 E6 and E7 in patients with cervical squamous cell carcinoma (CSCC). Also, the HLA-A allele distribution was compared among patients and evaluated as a factor to predict prognosis in these patients. MATERIALS AND METHODS: This study recruited a total of 76 patients with International Federation of Gynaecology and Obstetrics (FIGO) stage IIB-IIIB CSCC. Mononuclear cells were isolated from the peripheral blood before any treatment and then enzyme-linked immunosorbent spot (ELISpot) assay was employed to measure the E6 and E7-specific T cell response. HLA-A alleles were typed using Sanger sequencing-based typing techniques with DNA extracted from the peripheral blood. The correlation between the T cell responses, HLA-A allele distribution and patient prognosis were analysed using the Kaplan-Meier method, univariate and multivariate Cox proportional hazard models. RESULTS: The frequency of HPV E6-specific T cell responses in patients with pelvic lymph node metastasis was lower than that in patients without metastasis (P = 0.022). The 5-year overall survival (OS) rates of patients were 87.5% for those responding to multiple overlapping peptides, 72.7% for those responding to 1-2 overlapping peptides and 47.7% for non-responders (P = 0.032). Cox regression analysis indicated that the presence of HLA*A02:07 was independently associated with worse OS (hazard ratio [HR] 3.042; 95% confidence interval [CI] 1.348-6.862; P = 0.007), while concurrent chemoradiation therapy (CCRT) was independently associated with better OS (HR 0.475; 95% CI 0.232-0.975; P = 0.042). CONCLUSION: The results of our study demonstrated that the level of HPV16 E6-specific T cell response and HLA*A02:07 were correlated with prognosis in patients with advanced CSCC. CI - (c) 2021. The Author(s). FAU - Cai, Hongchao AU - Cai H AD - The Third Affiliated Hospital of Xinjiang Medical University, Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. AD - Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China. FAU - Feng, Yaning AU - Feng Y AD - The Third Affiliated Hospital of Xinjiang Medical University, Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. AD - Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China. AD - State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China. FAU - Fan, Peiwen AU - Fan P AD - The Third Affiliated Hospital of Xinjiang Medical University, Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. AD - Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China. AD - State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China. FAU - Guo, Yuping AU - Guo Y AD - The Third Affiliated Hospital of Xinjiang Medical University, Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. AD - Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China. FAU - Kuerban, Gulina AU - Kuerban G AD - The Third Affiliated Hospital of Xinjiang Medical University, Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. AD - Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China. FAU - Chang, Cheng AU - Chang C AD - The Third Affiliated Hospital of Xinjiang Medical University, Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. AD - Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China. FAU - Yao, Xuan AU - Yao X AD - Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), Oxford, UK. FAU - Peng, Yanchun AU - Peng Y AD - Chinese Academy of Medical Sciences Oxford Institute (CAMS Oxford Institute), Oxford, UK. FAU - Wang, Ruozheng AU - Wang R AD - The Third Affiliated Hospital of Xinjiang Medical University, Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. wrz8526@vip.163.com. AD - Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China. wrz8526@vip.163.com. AD - State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China. wrz8526@vip.163.com. LA - eng GR - XJ2019G187/Scientific Research and Innovation Project for postgraduates of Xinjiang Uygur Autonomous region/ GR - 2020E01056/The Special Projects of Regional Collaborative Innovation of the Autonomous region -- the SCO Scientific and Technological Partnership Program and the International Scientific and Technological Cooperation Program/ GR - 2019PT310021/The Key Laboratory of Cancer Immunotherapy and Radiotherapy, CAMS, China/ PT - Journal Article DEP - 20210916 PL - England TA - Infect Agent Cancer JT - Infectious agents and cancer JID - 101276559 PMC - PMC8447512 OTO - NOTNLM OT - Cervical cancer OT - E6 and E7 peptides OT - HLA OT - Human papillomavirus 16 OT - T cell immune response COIS- The authors declare that they have no competing interests. EDAT- 2021/09/18 06:00 MHDA- 2021/09/18 06:01 PMCR- 2021/09/16 CRDT- 2021/09/17 05:49 PHST- 2021/02/02 00:00 [received] PHST- 2021/07/20 00:00 [accepted] PHST- 2021/09/17 05:49 [entrez] PHST- 2021/09/18 06:00 [pubmed] PHST- 2021/09/18 06:01 [medline] PHST- 2021/09/16 00:00 [pmc-release] AID - 10.1186/s13027-021-00395-y [pii] AID - 395 [pii] AID - 10.1186/s13027-021-00395-y [doi] PST - epublish SO - Infect Agent Cancer. 2021 Sep 16;16(1):61. doi: 10.1186/s13027-021-00395-y.